SG11202112872YA - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith - Google Patents
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewithInfo
- Publication number
- SG11202112872YA SG11202112872YA SG11202112872YA SG11202112872YA SG11202112872YA SG 11202112872Y A SG11202112872Y A SG 11202112872YA SG 11202112872Y A SG11202112872Y A SG 11202112872YA SG 11202112872Y A SG11202112872Y A SG 11202112872YA SG 11202112872Y A SG11202112872Y A SG 11202112872YA
- Authority
- SG
- Singapore
- Prior art keywords
- isoindoline
- oxo
- substituted
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855619P | 2019-05-31 | 2019-05-31 | |
| PCT/US2020/035043 WO2020243379A1 (en) | 2019-05-31 | 2020-05-29 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112872YA true SG11202112872YA (en) | 2021-12-30 |
Family
ID=73551319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112872YA SG11202112872YA (en) | 2019-05-31 | 2020-05-29 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11306101B2 (en) |
| EP (1) | EP3976595A4 (en) |
| JP (1) | JP2022534979A (en) |
| KR (1) | KR20220016167A (en) |
| CN (2) | CN114269729A (en) |
| AR (1) | AR119057A1 (en) |
| AU (1) | AU2020282748A1 (en) |
| BR (1) | BR112021022758A2 (en) |
| CA (1) | CA3136753A1 (en) |
| CL (1) | CL2021003134A1 (en) |
| CO (1) | CO2021015624A2 (en) |
| IL (1) | IL288278A (en) |
| MX (1) | MX2021014350A (en) |
| PE (1) | PE20220569A1 (en) |
| SG (1) | SG11202112872YA (en) |
| TW (1) | TW202110819A (en) |
| WO (1) | WO2020243379A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20220569A1 (en) | 2019-05-31 | 2022-04-20 | Celgene Corp | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS OF THESE AND METHODS OF TREATMENT WITH SAID COMPOUNDS |
| CN112679421A (en) * | 2021-01-04 | 2021-04-20 | 都创(上海)医药科技股份有限公司 | Synthesis method of (R) -3-chloropyridyl-2-trifluoroethylamine hydrochloride |
| CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2022235900A1 (en) * | 2021-05-06 | 2022-11-10 | Celgene Corporation | Methods of treatment with n-((r)-1-(3-chloropyridin-2-yl)- 2,2,2-trifluoroethyl)-2-((s)-2,6-dioxopiperidin-3-yl)-1- oxoisoindoline-5-carboxamide |
| WO2022257897A1 (en) * | 2021-06-08 | 2022-12-15 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Isoindolinone compounds, and uses thereof |
| CN115504963A (en) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | C-Myc protein degradation agent |
| TW202346277A (en) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros zinc finger family degraders and uses thereof |
| WO2023244815A1 (en) * | 2022-06-16 | 2023-12-21 | Monte Rosa Therapeutics, Inc. | Molecular glue degraders and methods of using the same |
| WO2023244818A1 (en) * | 2022-06-16 | 2023-12-21 | Monte Rosa Therapeutics, Inc. | Molecular glue degraders and methods of using the same |
| WO2024027694A1 (en) * | 2022-08-01 | 2024-02-08 | 苏州开拓药业股份有限公司 | Protein degradation agent |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| ES2434946T3 (en) * | 2005-08-31 | 2013-12-18 | Celgene Corporation | Isoindol imide compounds and compositions comprising them and methods for using it |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| ZA200901078B (en) * | 2006-08-30 | 2010-06-30 | Celgene Corp | 5-substituted isoindoline compounds |
| WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| PE20220569A1 (en) | 2019-05-31 | 2022-04-20 | Celgene Corp | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS OF THESE AND METHODS OF TREATMENT WITH SAID COMPOUNDS |
-
2020
- 2020-05-29 PE PE2021001963A patent/PE20220569A1/en unknown
- 2020-05-29 AR ARP200101539A patent/AR119057A1/en unknown
- 2020-05-29 CA CA3136753A patent/CA3136753A1/en active Pending
- 2020-05-29 MX MX2021014350A patent/MX2021014350A/en unknown
- 2020-05-29 WO PCT/US2020/035043 patent/WO2020243379A1/en unknown
- 2020-05-29 EP EP20812650.8A patent/EP3976595A4/en active Pending
- 2020-05-29 SG SG11202112872YA patent/SG11202112872YA/en unknown
- 2020-05-29 AU AU2020282748A patent/AU2020282748A1/en active Pending
- 2020-05-29 CN CN202080040212.6A patent/CN114269729A/en active Pending
- 2020-05-29 CN CN202210612012.4A patent/CN114957212A/en active Pending
- 2020-05-29 US US16/887,766 patent/US11306101B2/en active Active
- 2020-05-29 JP JP2021570866A patent/JP2022534979A/en active Pending
- 2020-05-29 TW TW109117973A patent/TW202110819A/en unknown
- 2020-05-29 KR KR1020217042866A patent/KR20220016167A/en unknown
- 2020-05-29 BR BR112021022758A patent/BR112021022758A2/en unknown
-
2021
- 2021-11-21 IL IL288278A patent/IL288278A/en unknown
- 2021-11-22 CO CONC2021/0015624A patent/CO2021015624A2/en unknown
- 2021-11-24 CL CL2021003134A patent/CL2021003134A1/en unknown
-
2022
- 2022-03-09 US US17/690,921 patent/US20220213115A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR119057A1 (en) | 2021-11-17 |
| EP3976595A4 (en) | 2023-01-04 |
| MX2021014350A (en) | 2022-02-21 |
| US11306101B2 (en) | 2022-04-19 |
| US20200377512A1 (en) | 2020-12-03 |
| EP3976595A1 (en) | 2022-04-06 |
| AU2020282748A1 (en) | 2021-12-09 |
| KR20220016167A (en) | 2022-02-08 |
| PE20220569A1 (en) | 2022-04-20 |
| WO2020243379A1 (en) | 2020-12-03 |
| CN114269729A (en) | 2022-04-01 |
| TW202110819A (en) | 2021-03-16 |
| CL2021003134A1 (en) | 2022-07-01 |
| IL288278A (en) | 2022-01-01 |
| US20220213115A1 (en) | 2022-07-07 |
| BR112021022758A2 (en) | 2022-03-22 |
| JP2022534979A (en) | 2022-08-04 |
| CA3136753A1 (en) | 2020-12-03 |
| CO2021015624A2 (en) | 2022-02-28 |
| CN114957212A (en) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288278A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| IL262007A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| EP3675859A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| IL285782A (en) | Compounds, compositions, and methods for the treatment of disease | |
| IL285302A (en) | Compounds, compositions and methods | |
| HK1259372A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
| MX2018006700A (en) | Aza-benzimidazole inhibitors of pad4. | |
| IL283968A (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP3471722A4 (en) | Compounds, compositions and methods for prevention and/or treatment of cancer | |
| IL282939A (en) | Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof | |
| IL287120A (en) | Compounds, compositions and methods | |
| EP3612184A4 (en) | Compounds, compositions and methods of treating or preventing acute lung injury | |
| SG11202011041YA (en) | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof | |
| ZA202007320B (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| GB201915828D0 (en) | Compounds, compositions and therapeutic uses thereof | |
| EP3820477A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| IL268318A (en) | Compounds, compositions and uses thereof for improvement of bone disorders | |
| EP3719032A4 (en) | Composition for prevention or treatment of hair loss | |
| EP4135687A4 (en) | Polycannabinoids, compounds, compositions and methods of use | |
| IL289687A (en) | Compositions for the treatment of hair loss | |
| EP3917923A4 (en) | Compounds, compositions and methods for treatment of myopia | |
| GB201810923D0 (en) | Compositions and method of treatment | |
| GB201901219D0 (en) | Compositions and methods of treatment | |
| EP3886831A4 (en) | Compositions for treatment of symphysiolysis |